# US 2021/0267978 A1 · Nanoparticle formulations of ike and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267978 A1
- Document ID: US20210267978A1
- Status: Published application
- Kind: A1
- Application number: 17/307,605
- Filed: 2021-05-04
- Published: 2021-09-02
- Earliest claimed: 2018-11-07
- Applicants: The Trustees of Columbia University in the City of New York
- Inventors: Brent R. Stockwell; Yan Zhang
- Web page: https://patentgrep.com/patent/US20210267978A1

## CPC

- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5545: {having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61P 35/00: Antineoplastic agents
- C07D 239/91: with aryl or aralkyl radicals attached in position 2 or 3
- C07D 403/10: linked by a carbon chain containing aromatic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure provides, inter alia, nanoparticle formulations comprising nanoparticles of a polymer loaded with a system xc− inhibitor, such as a nanoparticle formulation comprising nanoparticles of PEG-PLGA loaded with IKE or a pharmaceutically acceptable salt thereof. Methods of preparing such nanoparticle formulations, methods of treating cancers in a subject or selectively killing cancer cells using such nanoparticle formulations, and kits comprising such nanoparticle formulations are also provided.

## Claims

### Claim 1

A nanoparticle formulation comprising nanoparticles of a polymer loaded with a system xc− inhibitor.

### Claim 2 (depends on 1)

The nanoparticle formulation of claim 1, wherein the polymer is biodegradable.

### Claim 3 (depends on 1)

The nanoparticle formulation of claim 1, wherein the polymer is selected from poly(lactic acid) (PLA), poly(lactide-co-glycolide) (PLGA), and poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA).

### Claim 4 (depends on 1)

The nanoparticle formulation of claim 1, wherein the polymer is poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA).

### Claim 5 (depends on 1)

The nanoparticle formulation of claim 1, wherein the system xc− inhibitor is a small molecule.

### Claim 6 (depends on 1)

The nanoparticle formulation of claim 1, wherein the system xc− inhibitor is an erastin analog.

### Claim 7 (depends on 1)

The nanoparticle formulation of claim 1, wherein the system xc− inhibitor is selected from
or pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 1)

The nanoparticle formulation of claim 1, wherein the system xc− inhibitor is IKE or pharmaceutically acceptable salts thereof.

### Claim 9 (depends on 1)

The nanoparticle formulation of claim 1, wherein the loaded nanoparticle has a size between 20 nm and 200 nm.

### Claim 10 (depends on 1)

The nanoparticle formulation of claim 1, wherein the loaded nanoparticle has a size of about 80 nm.

### Claim 11 (depends on 1)

The nanoparticle formulation of claim 1, wherein the loaded nanoparticle has a surface potential of about −17 mV.

### Claim 12 (depends on 1)

The nanoparticle formulation of claim 1, having a polydispersity index of about 0.2.

### Claim 13 (depends on 1)

The nanoparticle formulation of claim 1, having an encapsulation efficiency of about 24%.

### Claim 14

A nanoparticle formulation comprising nanoparticles of PEG-PLGA loaded with IKE or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

A method of preparing the nanoparticle formulation according to claim 14, comprising the steps of:
(a) assembling the nanoparticles by employing a NanoAssemblr platform equipped with a high flow microfluidic chip, using the following settings:
i) 1:1 ratio of organic to aqueous phases,
ii) 25% acetone/75% dimethyl sulfoxide (DMSO) as the organic phase, 10 mg/mL poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) in organic phase, and 15% (by weight) IKE to PEG-PLGA polymer in the organic phase;
iii) pure water as the aqueous phase;
iv) total flow rate of 8 mL/min; and
(b) concentrating the assembled nanoparticles by using filter units with concentration factors up to 20.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method for treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of a nanoparticle formulation according to any one of claims 1 to 14.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is diffuse large B cell lymphoma (DLBCL).

### Claim 18 (depends on 16)

The method of claim 16, wherein the nanoparticle formulation is administered at up to 750 mg/kg per day.

### Claim 19 (depends on 16)

The method of claim 16, further comprising co-administering to the subject a chemotherapy drug selected from the group consisting of cisplatin, temozolomide, doxorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, vinorelbine, docetaxel, bleomycin, vinblastine, dacarbazine, mustine, vincristine, procarbazine, prednisolone, etoposide, epirubicin, capecitabine, methotrexate, folinic acid, oxaliplatin, and combinations thereof.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method for selectively killing a cancer cell, comprising contacting the cancer cell with an effective amount of a nanoparticle formulation according to any one of claims 1 to 14.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A kit comprising a nanoparticle formulation according to any one of claims 1 to 14 together with instructions for the use of the nanoparticle formulation.
